The combination of immune checkpoint inhibitors and anti-angiogenic agents is a promising
new approach in cancer treatment. Immune checkpoint inhibitors block the signals that help …

Lung cancer remains the first cause of cancer-related death despite many therapeutic
innovations, including immune checkpoint inhibitors (ICI). ICI are now well used in daily …

Apatinib is a multitarget tyrosine kinase inhibitor marketed in China for the treatment of
advanced gastric cancer (GC) and hepatocellular carcinoma (HCC). It has also been used …

Immunotherapy has changed the treatment strategy of non-small cell lung cancer (NSCLC)
in recent years, among which anti-PD-1/PD-L1 antibodies are the most used. However, the …

Immune checkpoint blockade has vastly changed the landscape of cancer treatment and
showed a promising prognosis for cancer patients. However, there is still a large portion of …

Along with the positioning of immunotherapy as a preferential treatment for a wide variety of
neoplasms, a new pattern of response consisting in a sudden acceleration of tumor growth …

Hepatocellular carcinoma (HCC) is the most common primary liver cancer worldwide. The
onset of the disease is occult and develops rapidly. As a result, the disease is often detected …

Background In the last decade, immune checkpoint inhibitors have revolutionized the
treatment of metastatic nonsmall cell lung cancer without oncogenic addiction. Currently …

Background The use of circulating tumor DNA (ctDNA) to reflect clinical benefits of advanced
non-small cell lung cancer (NSCLC) patients during immune checkpoint inhibitor (ICI) …

Background This study aimed to explore the prognostic value of tumor mutational burden
(TMB) combined with smoking status in advanced non‐small cell lung cancer (NSCLC) …